The Cooper Companies, Inc. (COO) 10-Q 6 Mar 20 2020 Q1 Quarterly report Financial data

Cover Page

Cover Page - shares	3 Months Ended
	Jan. 31, 2020	Feb. 26, 2020
Cover page.
Document Type	10-Q
Document Quarterly Report	true
Document Period End Date	Jan. 31, 2020
Document Transition Report	false
Entity File Number	1-8597
Entity Registrant Name	The Cooper Companies, Inc.
Entity Incorporation, State or Country Code	DE
Entity Tax Identification Number	94-2657368
Entity Address, Address Line One	6101 Bollinger Canyon Road
Entity Address, Address Line Two	Suite 500
Entity Address, City or Town	San Ramon
Entity Address, State or Province	CA
Entity Address, Postal Zip Code	94583
City Area Code	925
Local Phone Number	460-3600
Title of 12(b) Security	Common Stock, $.10 par value
Trading Symbol	COO
Security Exchange Name	NYSE
Entity Current Reporting Status	Yes
Entity Interactive Data Current	Yes
Entity Filer Category	Large Accelerated Filer
Entity Small Business	false
Entity Emerging Growth Company	false
Entity Shell Company	false
Entity Common Stock, Shares Outstanding		53,330,450
Entity Central Index Key	0000711404
Document Fiscal Year Focus	2020
Document Fiscal Period Focus	Q1
Current Fiscal Year End Date	--10-31
Amendment Flag	false

Consolidated Statements of Inco

Consolidated Statements of Income - USD ($) shares in Millions, $ in Millions	3 Months Ended
	Jan. 31, 2020	Jan. 31, 2019
Income Statement [Abstract]
Net sales	$ 646.2	$ 628.1
Cost of sales	219.7	209.6
Gross profit	426.5	418.5
Selling, general and administrative expense	258.3	250
Research and development expense	22.2	21
Amortization of intangibles	34.9	36.6
Operating income	111.1	110.9
Interest expense	11.6	18.2
Other expense (income), net	2.1	(1.1)
Income before income taxes	97.4	93.8
Provision (benefit) for income taxes (Note 7)	6.9	(9.4)
Net income	$ 90.5	$ 103.2
Earnings per share - basic (in dollars per share) (Note 8)	$ 1.84	$ 2.09
Earnings per share - diluted (in dollars per share) (Note 8)	$ 1.82	$ 2.07
Number of shares used to compute earnings per share:
Basic (in shares)	49.1	49.3
Diluted (in shares)	49.7	49.9

Consolidated Condensed Balance

Consolidated Condensed Balance Sheets - USD ($) $ in Millions	Jan. 31, 2020	Oct. 31, 2019
Current assets:
Cash and cash equivalents	$ 76.8	$ 89
Trade accounts receivable, net of allowance for doubtful accounts of $15.2 at January 31, 2020 and $16.4 at October 31, 2019	408	435.3
Inventories	526.5	506.9
Prepaid expense and other current assets	138.6	132.2
Total current assets	1,149.9	1,163.4
Property, plant and equipment, at cost	2,266.9	2,193.9
Less: accumulated depreciation and amortization	1,098.4	1,061.8
Property, plant and equipment, net	1,168.5	1,132.1
Operating lease right-of-use assets (Note 2)	264
Goodwill (Note 5)	2,445.9	2,428.9
Other intangibles, net (Note 5)	1,374.4	1,405.3
Deferred tax assets	75.9	78
Other assets	69.9	66.8
Total assets	6,548.5	6,274.5
Current liabilities:
Short-term debt (Note 6)	543	563.7
Accounts payable	141.7	150.1
Employee compensation and benefits	92.5	104.7
Operating lease liabilities	31.5
Other current liabilities	259.8	292.1
Total current liabilities	1,068.5	1,110.6
Long-term debt (Note 6)	1,233.7	1,262.6
Deferred tax liabilities	27.6	28
Long-term tax payable	176.2	124.8
Operating lease liabilities	241.2
Accrued pension liability and other	70.4	119.9
Total liabilities	2,817.6	2,645.9
Contingencies (Note 13)
Stockholders’ equity:
Preferred stock, 10 cents par value, shares authorized: 1.0; zero shares issued or outstanding	0	0
Common stock, 10 cents par value, shares authorized: 120.0; issued 53.3 at January 31, 2020 and 53.2 at October 31, 2019	5.3	5.3
Additional paid-in capital	1,611.6	1,615
Accumulated other comprehensive loss	(430.4)	(447.1)
Retained earnings	3,115.4	3,026.4
Treasury stock at cost: 4.1 shares at January 31, 2020 and October 31, 2019	(571.2)	(571.2)
Total Cooper stockholders’ equity	3,730.7	3,628.4
Noncontrolling interests	0.2	0.2
Stockholders’ equity (Note 10)	3,730.9	3,628.6
Total liabilities and stockholders’ equity	$ 6,548.5	$ 6,274.5

Consolidated Statements of Comp

Consolidated Statements of Comprehensive Income - USD ($) $ in Millions	3 Months Ended
	Jan. 31, 2020	Jan. 31, 2019
Statement of Comprehensive Income [Abstract]
Net income	$ 90.5	$ 103.2
Other comprehensive income:
Foreign currency translation adjustment, net of tax	16.7	32.7
Comprehensive income	$ 107.2	$ 135.9

Consolidated Condensed Balanc_2

Consolidated Condensed Balance Sheets (Parenthetical) - USD ($) $ in Millions	Jan. 31, 2020	Oct. 31, 2019
Statement of Financial Position [Abstract]
Trade accounts receivable, allowance for doubtful accounts	$ 15.2	$ 16.4
Preferred stock, par value (in dollars per share)	$ 0.1	$ 0.1
Preferred stock, authorized (in shares)	1,000,000	1,000,000
Preferred stock, issued (in shares)	0	0
Preferred stock, outstanding (in shares)	0	0
Common stock, par value (in dollars per share)	$ 0.1	$ 0.1
Common stock, authorized (in shares)	120,000,000	120,000,000
Common stock, issued (in shares)	53,300,000	53,200,000
Treasury stock (in shares)	4,100,000	4,100,000

Consolidated Condensed Statemen

Consolidated Condensed Statements of Stockholders' Equity - USD ($) shares in Millions, $ in Millions	Total	Common Shares	Treasury Stock	Treasury Stock Par Net Value	Additional Paid-In Capital	Accumulated Other Comprehensive Income (Loss)	Retained Earnings	Noncontrolling Interests
Beginning balance (in shares) at Oct. 31, 2018		49.2	3.6
Beginning balance at Oct. 31, 2018	$ 3,307.8	$ 5	$ (415.1)	$ 0.3	$ 1,572.1	$ (430.7)	$ 2,576	$ 0.2
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Net income (loss)	103.2						103.2
Other comprehensive income (loss), net of tax	32.7					32.7
Issuance of common stock for stock plans, net (in shares)		0.1
Issuance of common stock for stock plans, net	(9)	$ 0			(9)
Treasury stock repurchase	(6.1)		$ (6.1)
Share-based compensation expense	(1.5)						(1.5)
ASU 2016-16 adoption	11.7				11.7
Ending balance (in shares) at Jan. 31, 2019		49.3	3.6
Ending balance at Jan. 31, 2019	3,425.5	$ 5	$ (421.2)	0.3	1,574.8	(398)	2,664.4	0.2
Beginning balance (in shares) at Oct. 31, 2018		49.2	3.6
Beginning balance at Oct. 31, 2018	3,307.8	$ 5	$ (415.1)	0.3	1,572.1	(430.7)	2,576	0.2
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Treasury stock repurchase	(156.1)
Ending balance (in shares) at Oct. 31, 2019		49.1	4.1
Ending balance at Oct. 31, 2019	3,628.6	$ 4.9	$ (571.2)	0.4	1,615	(447.1)	3,026.4	0.2
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Net income (loss)	90.5						90.5
Other comprehensive income (loss), net of tax	16.7					16.7
Issuance of common stock for stock plans, net (in shares)		0.1
Issuance of common stock for stock plans, net	(13.1)				(13.2)
Share-based compensation expense	(1.5)						(1.5)
ASU 2016-16 adoption	9.7				9.7
Ending balance (in shares) at Jan. 31, 2020		49.2	4.1
Ending balance at Jan. 31, 2020	$ 3,730.9	$ 4.9	$ (571.2)	$ 0.4	$ 1,611.6	$ (430.4)	$ 3,115.4	$ 0.2

Consolidated Condensed Statem_2

Consolidated Condensed Statements of Cash Flows - USD ($) $ in Millions	3 Months Ended
	Jan. 31, 2020	Jan. 31, 2019
Cash flows from operating activities:
Net income	$ 90.5	$ 103.2
Depreciation and amortization	70.6	68.8
Increase in operating capital	(50.6)	(53.3)
Other non-cash items	19.2	(16.9)
Net cash provided by operating activities	129.7	101.8
Cash flows from investing activities:
Purchases of property, plant and equipment	(69)	(79.2)
Acquisitions of businesses and assets, net of cash acquired, and other	(9.4)	(50)
Net cash used in investing activities	(78.4)	(129.2)
Cash flows from financing activities:
Proceeds from long-term debt	234	261.8
Repayments of long-term debt	(263.1)	(560.8)
Net (repayments) proceeds from short-term debt	(20.8)	407.5
Net payments related to share-based compensation awards	(13.2)	(9)
Repurchase of common stock	0	(6.1)
Debt acquisition costs	(0.1)	(0.2)
Net cash (used in) provided by financing activities	(63.2)	93.2
Effect of exchange rate changes on cash, cash equivalents and restricted cash	(0.2)	0.9
Net (decrease) increase in cash, cash equivalents and restricted cash	(12.1)	66.7
Cash, cash equivalents and restricted cash at beginning of period	89.5	80.2
Cash, cash equivalents and restricted cash at end of period	77.4	146.9
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents [Abstract]
Total cash, cash equivalents and restricted cash	$ 77.4	$ 146.9

General

General	3 Months Ended
	Jan. 31, 2020
Organization, Consolidation and Presentation of Financial Statements [Abstract]
General	General The accompanying unaudited interim consolidated condensed financial statements and related notes should be read in conjunction with the audited Consolidated Financial Statements of the Cooper Companies, Inc. and its subsidiaries (the Company) and related notes as contained in the Company’s Annual Report on Form 10-K for the fiscal year ended October 31, 2019. The unaudited interim financial statements include all adjustments (consisting only of normal recurring adjustments) and accruals necessary in the judgment of management for a fair statement of the results for the periods presented. Readers should not assume that the results reported here either indicate or guarantee future performance. The terms "the Company", "we", "us", and "our" are used to refer collectively to the Cooper Companies, Inc. and its subsidiaries. Accounting Policies There have been no material changes to our significant accounting policies described in our Annual Report on Form 10-K for the fiscal year ended October 31, 2019, except as it relates to the adoption of Accounting Standards Update (ASU) 2016-02, Leases (Topic 842) , which is described below. Leases We consider an arrangement a lease if the arrangement transfers the right to control the use of an identified asset in exchange for consideration. We have operating leases, but do not have material financing leases. Lease right-of-use assets represent the right to use an underlying asset for the lease term, and lease liabilities represent the obligation to make payments arising from the lease agreement. These assets and liabilities are recognized at the commencement of the lease based upon the present value of the future minimum lease payments over the lease term. The lease term reflects the noncancelable period of the lease together with periods covered by an option to extend or terminate the lease when management is reasonably certain that it will exercise such option. Changes in the lease term assumption could impact the right-of-use assets and lease liabilities recognized on the balance sheet. As our leases typically do not contain a readily determinable implicit rate, we determine the present value of the lease liability using our incremental borrowing rate at the lease commencement date based on the lease term on a collateralized basis. Accounting Pronouncements Recently Adopted I n February 2016, the Financial Accounting Standards Board (FASB) issued ASU 2016-02, Leases (Topic 842) . ASU 2016-02 requires that a lessee recognize the assets and liabilities that arise from operating leases. A lessee should recognize in the statement of financial position a liability to make lease payments (the lease liability) and a right-of-use (ROU) asset representing its right to use the underlying asset for the lease term. For leases with a term of 12 months or less, a lessee is permitted to make an accounting policy election by class of underlying asset not to recognize lease assets and lease liabilities. In transition, lessees and lessors are required to recognize and measure leases at the beginning of the earliest period presented using a modified retrospective approach. In July 2018, the FASB issued ASU 2018-10, Codification Improvements to Topic 842, Leases and ASU 2018-11, Leases Topic 842 Target improvements, which provides an additional (and optional) transition method whereby the new lease standard is applied at the adoption date and recognized as an adjustment to retained earnings. In March 2019, the FASB issued ASU 2019-01, Leases (Topic 842) Codification Improvements , which further clarifies the determination of fair value of the underlying asset by lessors that are not manufacturers or dealers and modifies transition disclosure requirements for changes in accounting principles and other technical updates. We adopted this standard using the optional transition method and recorded an adjustment to the Consolidated Condensed Balance Sheet on November 1, 2019. We have implemented changes to certain business processes, systems and internal controls to support adoption of the new standard and the related disclosure requirements, including the implementation of a third-party leasing software solution. We elected the package of transition expedients, which allows us to keep our existing lease classifications and not reassess whether any existing contracts as of the date of adoption are leases or contain leases and not reassess initial direct cost. In addition, we elected the practical expedients to combine lease and non-lease components for our leases, and for leases with an initial term of 12 months or less to recognize the associated lease payments in the Consolidated Statements of Income on a straight-line basis over the lease term. As of January 31, 2020 , the aggregate balances of lease right-of-use assets and lease liabilities were $264.0 million and $272.7 million , respectively. The standard did not affect our Consolidated Statements of Income or Consolidated Condensed Statements of Cash Flows. We will continue to disclose comparative reporting periods prior to November 1, 2019 under the previous accounting guidance, ASC 840 Leases. Accounting Pronouncements Issued Not Yet Adopted In June 2016, the FASB issued ASU No. 2016-13, “Financial Instruments-Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments ” and subsequent amendments to the initial guidance: ASU 2018-19 “Codification Improvements to Topic 326, Financial Instruments-Credit Losses ”, ASU 2019-04 “ Codification Improvements to Topic 326, Financial Instruments-Credit Losses, Topic 815, Derivatives and Hedging, and Topic 825, Financial Instruments” , ASU 2019-05 “ Financial Instruments-Credit Losses ”, ASU 2019-11 “ Codification Improvements to Topic 326, Financial Instruments - Credit Losses” (collectively, “Topic 326”) and ASU 2020-02 Financial Instruments—Credit Losses (Topic 326) and Leases (Topic 842). Topic 326 requires measurement and recognition of expected credit losses for financial assets held. Topic 326 is effective for fiscal years and interim periods within those fiscal years beginning after December 15, 2019, which means it will be effective for our fiscal year beginning November 01, 2020. Early adoption is permitted. We are currently evaluating the impact of Topic 326 on our consolidated financial statements. In November 2018, the FASB issued ASU 2018-18, Collaborative Arrangements (Topic 808), Clarifying the Interaction between Topic 808 and Topic 606. This guidance amended Topic 808 and Topic 606 to clarify that transactions in a collaborative arrangement should be accounted for under Topic 606 when the counterparty is a customer for a distinct good or service (i.e., unit of account). The amendments preclude an entity from presenting consideration from a transaction in a collaborative arrangement as revenue from contracts with customers if the counterparty is not a customer for that transaction. This guidance is effective for fiscal years, and interim periods within those fiscal years, beginning after December 15, 2019, which means it will be effective for our fiscal year beginning November 1, 2020. Early adoption is permitted. The adoption of this guidance will not have a material impact on our Consolidated Financial Statements. In December 2019, the FASB issued ASU 2019-12, Income Taxes (Topic 740): Simplifying the Accounting for Income Taxes. This guidance removes certain exceptions to the general principles in Topic 740 and enhances and simplifies various aspects of the income tax accounting guidance, including requirements such as tax basis step-up in goodwill obtained in a transaction that is not a business combination, ownership changes in investments, and interim-period accounting for enacted changes in tax law. This standard is effective for fiscal years and interim periods within those fiscal years beginning after December 15, 2020. Early adoption is permitted. We are currently evaluating the impact of ASU 2019-12 on our consolidated financial statements, which is effective for the Company in our fiscal year and interim periods beginning on November 1, 2021. In January 2020, the FASB issued ASU 2020-01 Investments-Equity Securities (Topic 321), Investments-Equity Method and Joint Ventures (Topic 323), and Derivatives and Hedging (Topic 815) - Clarifying the Interactions between Topic 321, Topic 323, and Topic 815. This guidance addresses accounting for the transition into and out of the equity method and provides clarification of the interaction of rules for equity securities, the equity method of accounting, and forward contracts and purchase options on certain types of securities. This standard is effective for fiscal years and interim periods within those fiscal years beginning after December 15, 2020. Early adoption is permitted. We are currently evaluating the impact of ASU 2020-01 which is effective for the Company in our fiscal year and interim periods beginning on November 1, 2021.

Leases

Leases	3 Months Ended
	Jan. 31, 2020
Leases [Abstract]
Leases	Leases The Company primarily has operating leases for office, manufacturing and warehouse space, vehicles, and office equipment. Our leases expire on various dates between 2021 and 2046, some of which could include options to extend the lease. Lease right-of-use assets and liabilities are recognized at the commencement date based on the present value of lease payments over the lease term. As these leases do not provide an implicit rate, we use our incremental borrowing rate based on the information available at the lease's commencement date in determining the present value of lease payments. We consider information including, but not limited to, the lease term, our credit rating and interest rates of similar debt instruments with comparable credit ratings and security interests. The lease right-of-use assets are increased by any lease prepayments made and reduced by any lease incentives such as tenant improvement allowances. Options to extend the lease term are included in the lease term when it is reasonably certain that we will exercise the extension option. The Company’s operating leases typically include non-lease components such as common-area maintenance costs. We have elected to include non-lease components with lease payments for the purpose of calculating lease right-of-use assets and liabilities, to the extent that they are fixed. Non-lease components that are not fixed are expensed as incurred as variable lease payments. Leases with a term of one year or less are not recognized on our Consolidated Condensed Balance Sheet, while the associated lease payments are recorded in the Consolidated Statements of Income on a straight-line basis over the lease term. Commitments under finance lease arrangements of $2.2 million as of January 31, 2020 are not significant and are not included in the disclosure tables below. The following table presents information about leases on the Consolidated Condensed Balance Sheet: (In millions) January 31, 2020 Operating Leases Operating lease right-of-use assets $ 264.0 Operating lease liabilities, current 31.5 Operating lease liabilities, non-current 241.2 Total operating lease liabilities $ 272.7 As of January 31, 2020 , the weighted average remaining lease term was 11.8 years and the weighted average discount rate was 3.0% . The following table presents information about lease expense in our Consolidated Statements of Income: Three Months Ended January 31, (In millions) 2020 Operating lease expense $ 9.9 Short-term lease expense 1.1 Variable lease expense 0.4 The following table presents supplemental cash flow information about the Company’s leases: Three Months Ended January 31, (In millions) 2020 Cash paid for amounts included in the measurement of lease liabilities: Operating cash flows from operating leases $ 9.9 Maturity of Lease Liabilities The minimum rental payments required under operating leases that have initial or remaining noncancelable lease terms in excess of one year as of January 31, 2020 are: (In millions) Remainder of 2020 $ 29.0 2021 36.1 2022 32.3 2023 29.0 2024 27.3 2025 and thereafter 175.7 Total lease payments 329.4 Less: interest 56.7 Present value of lease liabilities $ 272.7 As previously disclosed in the Company’s Annual Report on Form 10-K for the year ended October 31, 2019, and under previous lease accounting standard ASC 840, Leases, the aggregate future noncancelable minimum rental payments on its operating leases, as of October 31, 2019, are as follows: (In millions) 2020 $ 38.5 2021 34.9 2022 31.2 2023 28.0 2024 26.5 2025 and thereafter 173.6 Total future minimum lease payments $ 332.7

Acquisitions

Acquisitions	3 Months Ended
	Jan. 31, 2020
Business Combination And Asset Acquisition [Abstract]
Acquisitions	Acquisitions The following is a summary of the allocation of the total purchase consideration for business and asset acquisitions that the Company completed during fiscal 2020 and 2019: (In millions) January 31, 2020 October 31, 2019 Technology $ — $ 12.3 Customer relationships 3.4 7.5 Trademarks — 10.2 Other — 0.1 Total identifiable intangible assets $ 3.4 $ 30.1 Goodwill 4.0 29.8 Net tangible assets 1.8 7.3 Total purchase price $ 9.2 $ 67.2 All the acquisitions were funded by cash generated from operations or facility borrowings. For business acquisitions, we recorded the tangible and intangible assets acquired and liabilities assumed at their fair values as of the applicable date of acquisition. For assets acquisitions, we recorded the tangible and intangible assets acquired and liabilities assumed at their estimated and relative fair values as of the applicable date of acquisition. We believe these acquisitions strengthen CooperSurgical's and CooperVision's businesses through the addition of new distributors or complementary products and services. Fiscal Year 2020 On December 13, 2019, CooperSurgical completed the acquisition of a privately-held distributor of in vitro fertilization (IVF) medical devices and systems. The purchase price allocation is preliminary and we are in the process of finalizing information and the corresponding impact on goodwill. The pro forma results of operations of this acquisition has not been presented because the effect of the business combination described above was not material to our consolidated results of operations. Fiscal Year 2019 On December 28, 2018, CooperVision completed the acquisition of Blanchard Contact Lenses. Blanchard is a privately-held scleral lens company, which expands CooperVision's specialty and scleral lens portfolio. On December 31, 2018, CooperSurgical completed the acquisition of Incisive Surgical Inc., a privately-held U.S. medical device company that develops mechanical surgical solutions for skin closure. The pro forma results of operations of these acquisitions have not been presented because the effects of the business combinations described above, individually and in the aggregate, were not material to our reported consolidated financial results.

Inventories

Inventories	3 Months Ended
	Jan. 31, 2020
Inventory Disclosure [Abstract]
Inventories	Inventories (In millions) January 31, 2020 October 31, 2019 Raw materials $ 133.3 $ 131.4 Work-in-process 12.5 13.3 Finished goods 380.7 362.2 Total inventories $ 526.5 $ 506.9 Inventories are stated at the lower of cost and net realizable value. Cost is computed using standard cost that approximates actual cost, on a first-in, first-out basis.

Intangible Assets

Intangible Assets	3 Months Ended
	Jan. 31, 2020
Goodwill and Intangible Assets Disclosure [Abstract]
Intangible Assets	Intangible Assets Goodwill (In millions) CooperVision CooperSurgical Total Balance at October 31, 2018 $ 1,742.9 $ 649.2 $ 2,392.1 Net additions 14.1 22.0 36.1 Translation 8.4 (7.7 ) 0.7 Balance at October 31, 2019 1,765.4 663.5 2,428.9 Net additions — 4.0 4.0 Translation 13.3 (0.3 ) 13.0 Balance at January 31, 2020 $ 1,778.7 $ 667.2 $ 2,445.9 The Company evaluates goodwill for impairment annually during the fiscal third quarter and when an event occurs or circumstances change such that it is reasonably possible that impairment may exist. The Company accounts for goodwill, evaluates and tests goodwill balances for impairment in accordance with related accounting standards. The Company performed an annual impairment assessment in third quarter of fiscal 2019, and its analysis indicated that there was no impairment of goodwill in reporting units. Other Intangible Assets January 31, 2020 October 31, 2019 (In millions) Gross Carrying Amount Accumulated Amortization Gross Carrying Amount Accumulated Amortization Weighted Average Amortization Period (in years) Intangible assets with definite lives: Trademarks $ 148.5 $ 29.8 $ 148.5 $ 27.3 14 Composite intangible asset 1,061.9 159.3 1,061.9 141.6 15 Technology 400.2 229.1 399.9 221.2 11 Customer relationships 361.4 200.1 357.6 194.0 13 License and distribution rights and other 27.8 16.0 27.9 15.3 11 1,999.8 $ 634.3 1,995.8 $ 599.4 14 Less: accumulated amortization and translation 634.3 599.4 Intangible assets with definite lives, net 1,365.5 1,396.4 Intangible assets with indefinite lives, net (1) 8.9 8.9 Total other intangibles, net $ 1,374.4 $ 1,405.3 (1) Intangible assets with indefinite lives include technology and trademarks. Balances include foreign currency translation adjustments. As of January 31, 2020 , the estimation of amortization expenses for intangible assets with definite lives is as follows: Fiscal years: (In millions) Remainder of 2020 $ 101.5 2021 135.0 2022 133.1 2023 130.9 2024 126.6 Thereafter 738.4 Total remaining amortization for intangible assets with definite lives $ 1,365.5 The Company assesses indefinite-lived intangible assets annually during the fiscal third quarter and both indefinite-lived and definite-lived intangible assets, when an event occurs or change in circumstances indicate that the carrying amount of an intangible asset may not be recoverable, in accordance with related accounting standards. The Company performed an annual impairment assessment in third quarter of fiscal 2019 and did not recognize any material intangible asset impairment charges.

Debt

Debt	3 Months Ended
	Jan. 31, 2020
Debt Disclosure [Abstract]
Debt	Debt (In millions) January 31, 2020 October 31, 2019 Overdraft and other credit facilities $ 43.0 $ 63.7 Term loans 500.0 500.0 Short-term debt $ 543.0 $ 563.7 Revolving credit 235.0 264.0 Term loans 1,000.0 1,000.0 Other 0.2 0.2 Less: unamortized debt issuance cost (1.5 ) (1.6 ) Long-term debt 1,233.7 1,262.6 Total debt $ 1,776.7 $ 1,826.3 $500 million Term Loan on September 27, 2019 On September 27, 2019 , the Company amended its existing senior unsecured term loan agreement entered into on November 1, 2018 (the 2018 Term Loan Agreement) to establish a new 364 -day senior unsecured term loan (the 2019 Term Loan Agreement) with the same parties as the 2018 Term Loan Agreement. The 2019 Term Loan Agreement modifies certain provisions of the 2018 Term Loan Agreement which, among other things, extended the maturity date to September 25, 2020 and increased the aggregate principal amount of the term loan facility from an original amount of $400 million to $500 million . The Company used the additional funds to partially repay outstanding borrowings under the 2017 Term Loan Agreement (as defined below). At January 31, 2020 , the Company had $500.0 million outstanding under the 2019 Term Loan Agreement. Amounts outstanding under the 2019 Term Loan Agreement will bear interest, at the Company's option, at either the base rate, or the adjusted LIBOR (each as defined in the 2019 Term Loan Agreement), plus, in each case, an applicable rate of 0.00% in respect of base rate loans and 0.60% in respect of adjusted LIBOR loans. The weighted average interest rate for the three months ended January 31, 2020 was 2.35% . The 2019 Term Loan Agreement contains customary restrictive covenants, as well as financial covenants that require the Company to maintain a certain Total Leverage Ratio and Interest Coverage Ratio (each as defined in the 2019 Term Loan Agreement) consistent with the 2016 Credit Agreement discussed below. $1.425 billion Term Loan on November 1, 2017 On November 1, 2017, in connection with the PARAGARD acquisition, the Company entered into a five -year, $1.425 billion , senior unsecured term loan agreement (the 2017 Term Loan Agreement) by and among the Company, the lenders party thereto and DNB Bank ASA, New York Branch, as administrative agent which matures on November 1, 2022. The Company used part of the facility to fund the PARAGARD acquisition and used the remainder of the funds to partially repay outstanding borrowings under our revolving credit agreement. Amounts outstanding under the 2017 Term Loan Agreement will bear interest, at our option, at either the base rate, or the adjusted LIBOR (each as defined in the 2017 Term Loan Agreement), plus, in each case, an applicable rate of, between 0.00% and 0.75% in respect of base rate loans and between 1.00% and 1.75% in respect of adjusted LIBOR loans, in each case in accordance with a pricing grid tied to the Total Leverage Ratio as defined in the 2017 Term Loan Agreement. The 2017 Term Loan Agreement contains customary restrictive covenants, as well as financial covenants that require the Company to maintain a certain Total Leverage Ratio and Interest Coverage Ratio (each as defined in the 2017 Term Loan Agreement) consistent with the 2016 Credit Agreement discussed below. At January 31, 2020 , the Company had $1.0 billion outstanding under the 2017 Term Loan Agreement. The interest rate on the 2017 Term Loan was 2.91% at January 31, 2020 . Revolving Credit and Term Loan Agreement on March 1, 2016 On March 1, 2016 , the Company entered into a Revolving Credit and Term Loan Agreement (the 2016 Credit Agreement), among the Company, CooperVision International Holding Company, LP, the lenders party thereto and KeyBank National Association, as administrative agent. The 2016 Credit Agreement provides for a multi-currency revolving credit facility in an aggregate principal amount of $1.0 billion (the 2016 Revolving Credit Facility) and a term loan facility in an aggregate principal amount of $830.0 million (the 2016 Term Loan Facility), each of which, unless terminated earlier, mature on March 1, 2021 . In addition, the Company has the ability from time to time to request an increase to the size of the 2016 Revolving Credit Facility or establish one or more new term loans under the 2016 Term Loan Facility in an aggregate amount up to $750.0 million , subject to the discretionary participation of the lenders. Amounts outstanding under the 2016 Credit Agreement will bear interest, at our option, at either the base rate, or the adjusted LIBOR or adjusted foreign currency rate (each as defined in the 2016 Credit Agreement), plus, in each case, an applicable rate of between 0.00% and 0.75% in respect of base rate loans and between 1.00% and 1.75% in respect of adjusted LIBOR or adjusted foreign currency rate loans, in each case in accordance with a pricing grid tied to the Total Leverage Ratio, as defined in the 2016 Credit Agreement. The Company pays an annual commitment fee that ranges from 0.125% to 0.25% of the unused portion of the 2016 Revolving Credit Facility depending on certain financial ratios. In addition to the annual commitment fee, the Company is also required to pay certain letter of credit and related fronting fees and other administrative fees pursuant to the terms of the 2016 Credit Agreement. At January 31, 2020 , the Company had no outstanding balance under the 2016 Term Loan Facility and $235.0 million outstanding under the 2016 Revolving Credit Facility. $763.8 million was available under the 2016 Revolving Credit Facility. The 2016 Credit Agreement contains customary restrictive covenants, as well as financial covenants that require us to maintain a certain Total Leverage Ratio and Interest Coverage Ratio, each as defined in the 2016 Credit Agreement: • Interest Coverage Ratio, as defined, to be at least 3.00 to 1.00 at all times. • Total Leverage Ratio, as defined, to be no higher than 3.75 to 1.00 . At January 31, 2020 , the Company was in compliance with the Interest Coverage Ratio at 15.26 to 1.00 and the Total Leverage Ratio at 1.82 to 1.00 for 2019 Term Loan Agreement, 2017 Term Loan Agreement, and 2016 Credit Agreement.

Income Taxes

Income Taxes	3 Months Ended
	Jan. 31, 2020
Income Tax Disclosure [Abstract]
Income Taxes	Income Taxes Effective Tax Rate The Company's effective tax rates were an expense of 7.1% and a benefit of 10.0% for the first quarter of fiscal 2020 and fiscal 2019, respectively. The increase in our effective tax rate for the first quarter of fiscal 2020 compared to fiscal 2019 was primarily due to tax benefits for settlement of tax audits and revisions to the provisional tax charges related to the 2017 Tax Cuts and Jobs Act during fiscal 2019. Our effective tax rate for the first quarter of fiscal 2020 was lower than the U.S. statutory tax rate because of discrete tax benefits and a favorable mix of income from our foreign jurisdictions with preferential tax rates. Total discrete tax benefits for the first quarter of fiscal 2020 were $3.8 million primarily relating to excess tax benefits from share-based compensation. Our effective tax rate for the first quarter of fiscal 2019 was lower than the U.S. statutory rate because of discrete tax benefits and favorable mix of income from our foreign jurisdictions with lower tax rates. We recognize the benefit from a tax position only if it is more likely than not that the position would be sustained upon audit based solely on the technical merits of the tax position. As of January 31, 2020 , and October 31, 2019, Cooper had unrecognized tax benefits of $54.8 million and $49.7 million , respectively. The increase is primarily related to additions to current and prior period transfer pricing reserves, partially offset by release of reserves due to lapse of the statute of limitations. It is our policy to recognize interest and penalties directly related to income taxes as additional income tax expense. It is reasonably possible that $14.8 million of unrecognized tax benefits could be settled during the next twelve months. The Company is subject to U.S. federal income tax examinations for fiscal 2015 through 2019 and the Internal Revenue Service is currently auditing our U.S. Consolidated Corporation Income Tax Returns for fiscal 2015 and 2016. The Company remains subject to income tax examinations in other significant tax jurisdictions including United Kingdom, Japan, France and Australia for the tax years 2014 through 2019. The Company is currently under audit in the United Kingdom for fiscal 2015 through 2018.

Earnings Per Share

Earnings Per Share	3 Months Ended
	Jan. 31, 2020
Earnings Per Share [Abstract]
Earnings Per Share	Earnings Per Share Three Months Ended January 31, (In millions, except per share amounts) 2020 2019 Net income $ 90.5 $ 103.2 Basic: Weighted average common shares 49.1 49.3 Basic earnings per share $ 1.84 $ 2.09 Diluted: Weighted average common shares 49.1 49.3 Effect of dilutive stock options 0.6 0.6 Diluted weighted average common shares 49.7 49.9 Diluted earnings per share $ 1.82 $ 2.07 The following table sets forth stock options to purchase our common stock and restricted stock units that were not included in the diluted earnings per share calculation because their effect would have been antidilutive for the periods presented: Three Months Ended January 31, (In thousands, except exercise prices) 2020 2019 Stock option shares excluded 198 377 Range of exercise prices $ 254.77 $226.30-$254.77 Restricted stock units excluded 1 17

Share-Based Compensation Plans

Share-Based Compensation Plans	3 Months Ended
	Jan. 31, 2020
Share-based Payment Arrangement [Abstract]
Share-Based Compensation Plans	Share-Based Compensation Plans The Company has several share-based compensation plans that are described in the Company’s Annual Report on Form 10‑K for the fiscal year ended October 31, 2019 . The compensation expense and related income tax benefit recognized in our Consolidated Statements of Income for share-based awards were as follows: Three Months Ended January 31, (In millions) 2020 2019 Selling, general and administrative expense $ 8.7 $ 9.3 Cost of sales 1.0 1.5 Research and development expense 0.6 0.9 Total share-based compensation expense $ 10.3 $ 11.7 Related income tax benefit $ 1.4 $ 1.7

Stockholders' Equity

Stockholders' Equity	3 Months Ended
	Jan. 31, 2020
Stockholders' Equity Note [Abstract]
Stockholders' Equity	Stockholders’ Equity Analysis of Changes in Accumulated Other Comprehensive (Loss) Income: (In millions) Foreign Currency Translation Adjustment Minimum Pension Liability Total Balance at October 31, 2018 $ (412.2 ) $ (18.5 ) $ (430.7 ) Gross change in value 9.0 (33.4 ) (24.4 ) Tax effect for the period — 8.0 8.0 Balance at October 31, 2019 $ (403.2 ) $ (43.9 ) $ (447.1 ) Gross change in value 16.7 — 16.7 Balance at January 31, 2020 $ (386.5 ) $ (43.9 ) $ (430.4 ) Share Repurchases In December 2011, our Board of Directors authorized the 2012 Share Repurchase Program and through subsequent amendments, the most recent in March 2017, the total repurchase authorization was increased from $500.0 million to $1.0 billion of the Company's common stock. This program has no expiration date and may be discontinued at any time. Purchases under the 2012 Share Repurchase Program are subject to a review of the circumstances in place at the time and may be made from time to time as permitted by securities laws and other legal requirements. There was no share repurchase activity during the first quarter ended January 31, 2020 . During fiscal year ended October 31, 2019 , we repurchased 537 thousand shares of our common stock for $156.1 million under the 2012 Share Repurchase Program. At January 31, 2020 , $407.4 million remained authorized for repurchase under the program. Dividends We paid a semiannual dividend of approximately $1.5 million or 3 cents per share on February 10, 2020, to stockholders of record on January 23, 2020 .

Fair Value Measurements

Fair Value Measurements	3 Months Ended
	Jan. 31, 2020
Fair Value Disclosures [Abstract]
Fair Value Measurements	Fair Value Measurements Accounting standards define fair value as the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. The fair value hierarchy prioritizes the inputs to valuation techniques used to measure fair value. An asset’s or liability’s level is based on the lowest level of input that is significant to the fair value measurement. Assets and liabilities carried at fair value are valued and disclosed in one of the following three levels of the valuation hierarchy: Level 1: Quoted market prices in active markets for identical assets or liabilities. Level 2: Observable market-based inputs or unobservable inputs that are corroborated by market data. Level 3: Unobservable inputs reflecting the reporting entity’s own assumptions. At January 31, 2020 and October 31, 2019 , the carrying value of cash and cash equivalents, accounts receivable, prepaid expense and other current assets, lines of credit, accounts payable and other current liabilities approximate fair value due to the short-term nature of such instruments and the ability to obtain financing on similar terms. The carrying value of our revolving credit facility and term loans approximates fair value estimated based on current market rates (Level 2). The Company did no t have any derivative assets or liabilities including no interest rate swaps, cross currency swaps or foreign currency forward contracts as of January 31, 2020 and October 31, 2019 . Nonrecurring fair value measurements

Employee Benefits

Employee Benefits	3 Months Ended
	Jan. 31, 2020
Retirement Benefits [Abstract]
Employee Benefits	Employee Benefits Cooper’s Retirement Income Plan (the Plan), a defined benefit plan, covers substantially all full-time United States employees. Cooper's contributions are designed to fund normal cost on a current basis and to fund the estimated prior service cost of benefit improvements. The unit credit actuarial cost method is used to determine the annual cost. Cooper pays the entire cost of the Plan and funds such costs as they accrue. Virtually all of the assets of the Plan are comprised of equities and participation in equity and fixed income funds. Our results of operations for the three months ended January 31, 2020 and 2019 , reflect the following components of net periodic defined benefit costs: Three Months Ended January 31, (In millions) 2020 2019 Service cost $ 3.5 $ 2.5 Interest cost 1.2 1.5 Expected return on plan assets (2.7 ) (2.4 ) Recognized net actuarial loss 1.0 0.2 Net periodic defined benefit plan cost $ 3.0 $ 1.8 We did no t contribute to the Plan in the first quarter of fiscal 2020 and expect to contribute $10.0 million during the remainder of fiscal 2020. We did no t contribute to the Plan in the first quarter of fiscal 2019. The expected rate of return on Plan assets for determining net periodic benefit plan cost is 8% .

Contingencies

Contingencies	3 Months Ended
	Jan. 31, 2020
Commitments and Contingencies Disclosure [Abstract]
Contingencies	Contingencies Since March 2015, over 50 putative class action complaints were filed by contact lens consumers alleging that contact lens manufacturers, in conjunction with their respective Unilateral Pricing Policy (UPP), conspired to reach agreements between each other and certain distributors and retailers regarding the prices at which certain contact lenses could be sold to consumers. The plaintiffs are seeking damages against CooperVision, Inc., other contact lens manufacturers, distributors and retailers, in various courts around the United States. In June 2015, all of the class action cases were consolidated and transferred to the United States District Court for the Middle District of Florida. In August 2017, CooperVision entered into a settlement agreement with the plaintiffs, without any admission of liability, to settle all claims against CooperVision. In July 2018, the Court approved the plaintiffs’ motion for preliminary approval of the settlement, and the Company paid the $3.0 million settlement amount into an escrow account. In March 2020, the Court issued an order providing final approval of the settlement and dismissing CooperVision from the class action. The Company is involved in various lawsuits, claims and other legal matters from time to time that arise in the ordinary course of conducting business, including matters involving our products, intellectual property, supplier relationships, distributors, competitor relationships, employees and other matters. The Company does not believe that the ultimate resolution of these proceedings or claims pending against it could have a material adverse effect on its financial condition or results of operations. At each reporting period, the Company evaluates whether or not a potential loss amount or a potential range of loss is probable and reasonably estimable under ASC 450, Contingencies . Legal fees are expensed as incurred.

Business Segment Information

Business Segment Information	3 Months Ended
	Jan. 31, 2020
Segment Reporting [Abstract]
Business Segment Information	Business Segment Information The Company discloses information about its operating segments, which were established based on the way that management organizes segments within the Company for making operating decisions and assessing financial performance. The Company's two operating segments are described below. • CooperVision. Competes in the worldwide contact lens market by developing, manufacturing and marketing a broad range of products for contact lens wearers, featuring advanced materials and optics. CooperVision designs its products to solve vision challenges such as astigmatism, presbyopia, myopia, ocular dryness and eye fatigues, with a broad collection of spherical, toric and multifocal contact lenses. • CooperSurgical. Competes in the general health care market with a focus on advancing the health of women, babies and families through a diversified portfolio of products and services focusing on women's health, fertility, diagnostics and contraception. Cooper uses operating income, as presented in our financial reports, as the primary measure of segment profitability. We do not allocate costs from corporate functions to segment operating income. Items below operating income are not considered when measuring the profitability of a segment. We use the same accounting policies to generate segment results as we do for our consolidated results. Total identifiable assets are those used in continuing operations except cash and cash equivalents, which we include as corporate assets. Segment information: Three Months Ended January 31, (In millions) 2020 2019 CooperVision net sales by category: Toric lens $ 155.1 $ 146.0 Multifocal lens 51.8 49.1 Single-use sphere lens 138.1 132.1 Non single-use sphere, other 140.2 142.9 Total CooperVision net sales $ 485.2 $ 470.1 CooperSurgical net sales by category: Office and surgical products 98.5 95.7 Fertility 62.5 62.3 CooperSurgical net sales 161.0 158.0 Total net sales $ 646.2 $ 628.1 Operating income: CooperVision $ 122.9 $ 116.3 CooperSurgical 1.7 7.2 Corporate (13.5 ) (12.6 ) Total operating income 111.1 110.9 Interest expense 11.6 18.2 Other expense (income), net 2.1 (1.1 ) Income before income taxes $ 97.4 $ 93.8 (In millions) January 31, 2020 October 31, 2019 Total identifiable assets: CooperVision $ 4,163.2 $ 3,911.6 CooperSurgical 2,226.6 2,189.8 Corporate 158.7 173.1 Total $ 6,548.5 $ 6,274.5 Geographic information: Three Months Ended January 31, (In millions) 2020 2019 Net sales to unaffiliated customers by country of domicile: United States $ 293.5 $ 278.9 Europe 213.4 209.7 Rest of world 139.3 139.5 Total $ 646.2 $ 628.1 (In millions) January 31, 2020 October 31, 2019 Net property, plant and equipment by country of domicile: United States $ 649.6 $ 626.5 Europe 361.9 358.8 Rest of world 157.0 146.8 Total $ 1,168.5 $ 1,132.1

General (Policies)

General (Policies)	3 Months Ended
	Jan. 31, 2020
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Leases	Leases We consider an arrangement a lease if the arrangement transfers the right to control the use of an identified asset in exchange for consideration. We have operating leases, but do not have material financing leases. Lease right-of-use assets represent the right to use an underlying asset for the lease term, and lease liabilities represent the obligation to make payments arising from the lease agreement. These assets and liabilities are recognized at the commencement of the lease based upon the present value of the future minimum lease payments over the lease term. The lease term reflects the noncancelable period of the lease together with periods covered by an option to extend or terminate the lease when management is reasonably certain that it will exercise such option. Changes in the lease term assumption could impact the right-of-use assets and lease liabilities recognized on the balance sheet. As our leases typically do not contain a readily determinable implicit rate, we determine the present value of the lease liability using our incremental borrowing rate at the lease commencement date based on the lease term on a collateralized basis.
Accounting Pronouncements Recently Adopted and Accounting Pronouncements Issued Not Yet Adopted	Accounting Pronouncements Recently Adopted I n February 2016, the Financial Accounting Standards Board (FASB) issued ASU 2016-02, Leases (Topic 842) . ASU 2016-02 requires that a lessee recognize the assets and liabilities that arise from operating leases. A lessee should recognize in the statement of financial position a liability to make lease payments (the lease liability) and a right-of-use (ROU) asset representing its right to use the underlying asset for the lease term. For leases with a term of 12 months or less, a lessee is permitted to make an accounting policy election by class of underlying asset not to recognize lease assets and lease liabilities. In transition, lessees and lessors are required to recognize and measure leases at the beginning of the earliest period presented using a modified retrospective approach. In July 2018, the FASB issued ASU 2018-10, Codification Improvements to Topic 842, Leases and ASU 2018-11, Leases Topic 842 Target improvements, which provides an additional (and optional) transition method whereby the new lease standard is applied at the adoption date and recognized as an adjustment to retained earnings. In March 2019, the FASB issued ASU 2019-01, Leases (Topic 842) Codification Improvements , which further clarifies the determination of fair value of the underlying asset by lessors that are not manufacturers or dealers and modifies transition disclosure requirements for changes in accounting principles and other technical updates. We adopted this standard using the optional transition method and recorded an adjustment to the Consolidated Condensed Balance Sheet on November 1, 2019. We have implemented changes to certain business processes, systems and internal controls to support adoption of the new standard and the related disclosure requirements, including the implementation of a third-party leasing software solution. We elected the package of transition expedients, which allows us to keep our existing lease classifications and not reassess whether any existing contracts as of the date of adoption are leases or contain leases and not reassess initial direct cost. In addition, we elected the practical expedients to combine lease and non-lease components for our leases, and for leases with an initial term of 12 months or less to recognize the associated lease payments in the Consolidated Statements of Income on a straight-line basis over the lease term. As of January 31, 2020 , the aggregate balances of lease right-of-use assets and lease liabilities were $264.0 million and $272.7 million , respectively. The standard did not affect our Consolidated Statements of Income or Consolidated Condensed Statements of Cash Flows. We will continue to disclose comparative reporting periods prior to November 1, 2019 under the previous accounting guidance, ASC 840 Leases. Accounting Pronouncements Issued Not Yet Adopted In June 2016, the FASB issued ASU No. 2016-13, “Financial Instruments-Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments ” and subsequent amendments to the initial guidance: ASU 2018-19 “Codification Improvements to Topic 326, Financial Instruments-Credit Losses ”, ASU 2019-04 “ Codification Improvements to Topic 326, Financial Instruments-Credit Losses, Topic 815, Derivatives and Hedging, and Topic 825, Financial Instruments” , ASU 2019-05 “ Financial Instruments-Credit Losses ”, ASU 2019-11 “ Codification Improvements to Topic 326, Financial Instruments - Credit Losses” (collectively, “Topic 326”) and ASU 2020-02 Financial Instruments—Credit Losses (Topic 326) and Leases (Topic 842). Topic 326 requires measurement and recognition of expected credit losses for financial assets held. Topic 326 is effective for fiscal years and interim periods within those fiscal years beginning after December 15, 2019, which means it will be effective for our fiscal year beginning November 01, 2020. Early adoption is permitted. We are currently evaluating the impact of Topic 326 on our consolidated financial statements. In November 2018, the FASB issued ASU 2018-18, Collaborative Arrangements (Topic 808), Clarifying the Interaction between Topic 808 and Topic 606. This guidance amended Topic 808 and Topic 606 to clarify that transactions in a collaborative arrangement should be accounted for under Topic 606 when the counterparty is a customer for a distinct good or service (i.e., unit of account). The amendments preclude an entity from presenting consideration from a transaction in a collaborative arrangement as revenue from contracts with customers if the counterparty is not a customer for that transaction. This guidance is effective for fiscal years, and interim periods within those fiscal years, beginning after December 15, 2019, which means it will be effective for our fiscal year beginning November 1, 2020. Early adoption is permitted. The adoption of this guidance will not have a material impact on our Consolidated Financial Statements. In December 2019, the FASB issued ASU 2019-12, Income Taxes (Topic 740): Simplifying the Accounting for Income Taxes. This guidance removes certain exceptions to the general principles in Topic 740 and enhances and simplifies various aspects of the income tax accounting guidance, including requirements such as tax basis step-up in goodwill obtained in a transaction that is not a business combination, ownership changes in investments, and interim-period accounting for enacted changes in tax law. This standard is effective for fiscal years and interim periods within those fiscal years beginning after December 15, 2020. Early adoption is permitted. We are currently evaluating the impact of ASU 2019-12 on our consolidated financial statements, which is effective for the Company in our fiscal year and interim periods beginning on November 1, 2021.

Leases (Tables)

Leases (Tables)	3 Months Ended
	Jan. 31, 2020
Leases [Abstract]
Leases on the Consolidated Condensed Balance Sheet	The following table presents information about leases on the Consolidated Condensed Balance Sheet: (In millions) January 31, 2020 Operating Leases Operating lease right-of-use assets $ 264.0 Operating lease liabilities, current 31.5 Operating lease liabilities, non-current 241.2 Total operating lease liabilities $ 272.7
Lease Cost	The following table presents information about lease expense in our Consolidated Statements of Income: Three Months Ended January 31, (In millions) 2020 Operating lease expense $ 9.9 Short-term lease expense 1.1 Variable lease expense 0.4 The following table presents supplemental cash flow information about the Company’s leases: Three Months Ended January 31, (In millions) 2020 Cash paid for amounts included in the measurement of lease liabilities: Operating cash flows from operating leases $ 9.9
Minimum Rental Payments required under Operating Leases	The minimum rental payments required under operating leases that have initial or remaining noncancelable lease terms in excess of one year as of January 31, 2020 are: (In millions) Remainder of 2020 $ 29.0 2021 36.1 2022 32.3 2023 29.0 2024 27.3 2025 and thereafter 175.7 Total lease payments 329.4 Less: interest 56.7 Present value of lease liabilities $ 272.7
Future Minimum Lease Payments for Operating Leases under ASC 840	As previously disclosed in the Company’s Annual Report on Form 10-K for the year ended October 31, 2019, and under previous lease accounting standard ASC 840, Leases, the aggregate future noncancelable minimum rental payments on its operating leases, as of October 31, 2019, are as follows: (In millions) 2020 $ 38.5 2021 34.9 2022 31.2 2023 28.0 2024 26.5 2025 and thereafter 173.6 Total future minimum lease payments $ 332.7

Acquisitions (Tables)

Acquisitions (Tables)	3 Months Ended
	Jan. 31, 2020
Business Combination And Asset Acquisition [Abstract]
Total purchase consideration for business and asset acquisitions	The following is a summary of the allocation of the total purchase consideration for business and asset acquisitions that the Company completed during fiscal 2020 and 2019: (In millions) January 31, 2020 October 31, 2019 Technology $ — $ 12.3 Customer relationships 3.4 7.5 Trademarks — 10.2 Other — 0.1 Total identifiable intangible assets $ 3.4 $ 30.1 Goodwill 4.0 29.8 Net tangible assets 1.8 7.3 Total purchase price $ 9.2 $ 67.2

Inventories (Tables)

Inventories (Tables)	3 Months Ended
	Jan. 31, 2020
Inventory Disclosure [Abstract]
Schedule of inventories	(In millions) January 31, 2020 October 31, 2019 Raw materials $ 133.3 $ 131.4 Work-in-process 12.5 13.3 Finished goods 380.7 362.2 Total inventories $ 526.5 $ 506.9

Intangible Assets (Tables)

Intangible Assets (Tables)	3 Months Ended
	Jan. 31, 2020
Goodwill and Intangible Assets Disclosure [Abstract]
Schedule of goodwill	Goodwill (In millions) CooperVision CooperSurgical Total Balance at October 31, 2018 $ 1,742.9 $ 649.2 $ 2,392.1 Net additions 14.1 22.0 36.1 Translation 8.4 (7.7 ) 0.7 Balance at October 31, 2019 1,765.4 663.5 2,428.9 Net additions — 4.0 4.0 Translation 13.3 (0.3 ) 13.0 Balance at January 31, 2020 $ 1,778.7 $ 667.2 $ 2,445.9
Schedule of finite-lived intangible assets	Other Intangible Assets January 31, 2020 October 31, 2019 (In millions) Gross Carrying Amount Accumulated Amortization Gross Carrying Amount Accumulated Amortization Weighted Average Amortization Period (in years) Intangible assets with definite lives: Trademarks $ 148.5 $ 29.8 $ 148.5 $ 27.3 14 Composite intangible asset 1,061.9 159.3 1,061.9 141.6 15 Technology 400.2 229.1 399.9 221.2 11 Customer relationships 361.4 200.1 357.6 194.0 13 License and distribution rights and other 27.8 16.0 27.9 15.3 11 1,999.8 $ 634.3 1,995.8 $ 599.4 14 Less: accumulated amortization and translation 634.3 599.4 Intangible assets with definite lives, net 1,365.5 1,396.4 Intangible assets with indefinite lives, net (1) 8.9 8.9 Total other intangibles, net $ 1,374.4 $ 1,405.3 (1)
Schedule of indefinite-lived intangible assets	Other Intangible Assets January 31, 2020 October 31, 2019 (In millions) Gross Carrying Amount Accumulated Amortization Gross Carrying Amount Accumulated Amortization Weighted Average Amortization Period (in years) Intangible assets with definite lives: Trademarks $ 148.5 $ 29.8 $ 148.5 $ 27.3 14 Composite intangible asset 1,061.9 159.3 1,061.9 141.6 15 Technology 400.2 229.1 399.9 221.2 11 Customer relationships 361.4 200.1 357.6 194.0 13 License and distribution rights and other 27.8 16.0 27.9 15.3 11 1,999.8 $ 634.3 1,995.8 $ 599.4 14 Less: accumulated amortization and translation 634.3 599.4 Intangible assets with definite lives, net 1,365.5 1,396.4 Intangible assets with indefinite lives, net (1) 8.9 8.9 Total other intangibles, net $ 1,374.4 $ 1,405.3 (1)
Remaining amortization expenses for intangible assets with definite lives	As of January 31, 2020 , the estimation of amortization expenses for intangible assets with definite lives is as follows: Fiscal years: (In millions) Remainder of 2020 $ 101.5 2021 135.0 2022 133.1 2023 130.9 2024 126.6 Thereafter 738.4 Total remaining amortization for intangible assets with definite lives $ 1,365.5

Debt (Tables)

Debt (Tables)	3 Months Ended
	Jan. 31, 2020
Debt Disclosure [Abstract]
Schedule of debt	(In millions) January 31, 2020 October 31, 2019 Overdraft and other credit facilities $ 43.0 $ 63.7 Term loans 500.0 500.0 Short-term debt $ 543.0 $ 563.7 Revolving credit 235.0 264.0 Term loans 1,000.0 1,000.0 Other 0.2 0.2 Less: unamortized debt issuance cost (1.5 ) (1.6 ) Long-term debt 1,233.7 1,262.6 Total debt $ 1,776.7 $ 1,826.3

Earnings Per Share (Tables)

Earnings Per Share (Tables)	3 Months Ended
	Jan. 31, 2020
Earnings Per Share [Abstract]
Schedule of earnings per share	Three Months Ended January 31, (In millions, except per share amounts) 2020 2019 Net income $ 90.5 $ 103.2 Basic: Weighted average common shares 49.1 49.3 Basic earnings per share $ 1.84 $ 2.09 Diluted: Weighted average common shares 49.1 49.3 Effect of dilutive stock options 0.6 0.6 Diluted weighted average common shares 49.7 49.9 Diluted earnings per share $ 1.82 $ 2.07
Schedule of stock options and restricted stock units that were not included in the diluted earnings per share calculation	The following table sets forth stock options to purchase our common stock and restricted stock units that were not included in the diluted earnings per share calculation because their effect would have been antidilutive for the periods presented: Three Months Ended January 31, (In thousands, except exercise prices) 2020 2019 Stock option shares excluded 198 377 Range of exercise prices $ 254.77 $226.30-$254.77 Restricted stock units excluded 1 17

Share-Based Compensation Plans

Share-Based Compensation Plans (Tables)	3 Months Ended
	Jan. 31, 2020
Share-based Payment Arrangement [Abstract]
Schedule of compensation expense and related income tax benefit for share-based awards	The compensation expense and related income tax benefit recognized in our Consolidated Statements of Income for share-based awards were as follows: Three Months Ended January 31, (In millions) 2020 2019 Selling, general and administrative expense $ 8.7 $ 9.3 Cost of sales 1.0 1.5 Research and development expense 0.6 0.9 Total share-based compensation expense $ 10.3 $ 11.7 Related income tax benefit $ 1.4 $ 1.7

Stockholders' Equity (Tables)

Stockholders' Equity (Tables)	3 Months Ended
	Jan. 31, 2020
Stockholders' Equity Note [Abstract]
Schedule of changes in accumulated other comprehensive (loss) income	Analysis of Changes in Accumulated Other Comprehensive (Loss) Income: (In millions) Foreign Currency Translation Adjustment Minimum Pension Liability Total Balance at October 31, 2018 $ (412.2 ) $ (18.5 ) $ (430.7 ) Gross change in value 9.0 (33.4 ) (24.4 ) Tax effect for the period — 8.0 8.0 Balance at October 31, 2019 $ (403.2 ) $ (43.9 ) $ (447.1 ) Gross change in value 16.7 — 16.7 Balance at January 31, 2020 $ (386.5 ) $ (43.9 ) $ (430.4 )

Employee Benefits (Tables)

Employee Benefits (Tables)	3 Months Ended
	Jan. 31, 2020
Retirement Benefits [Abstract]
Schedule of Components of Net Periodic Pension Costs	Our results of operations for the three months ended January 31, 2020 and 2019 , reflect the following components of net periodic defined benefit costs: Three Months Ended January 31, (In millions) 2020 2019 Service cost $ 3.5 $ 2.5 Interest cost 1.2 1.5 Expected return on plan assets (2.7 ) (2.4 ) Recognized net actuarial loss 1.0 0.2 Net periodic defined benefit plan cost $ 3.0 $ 1.8

Business Segment Information (T

Business Segment Information (Tables)	3 Months Ended
	Jan. 31, 2020
Segment Reporting [Abstract]
Schedule of segment information	Segment information: Three Months Ended January 31, (In millions) 2020 2019 CooperVision net sales by category: Toric lens $ 155.1 $ 146.0 Multifocal lens 51.8 49.1 Single-use sphere lens 138.1 132.1 Non single-use sphere, other 140.2 142.9 Total CooperVision net sales $ 485.2 $ 470.1 CooperSurgical net sales by category: Office and surgical products 98.5 95.7 Fertility 62.5 62.3 CooperSurgical net sales 161.0 158.0 Total net sales $ 646.2 $ 628.1 Operating income: CooperVision $ 122.9 $ 116.3 CooperSurgical 1.7 7.2 Corporate (13.5 ) (12.6 ) Total operating income 111.1 110.9 Interest expense 11.6 18.2 Other expense (income), net 2.1 (1.1 ) Income before income taxes $ 97.4 $ 93.8
Schedule of identifiable assets by segment	(In millions) January 31, 2020 October 31, 2019 Total identifiable assets: CooperVision $ 4,163.2 $ 3,911.6 CooperSurgical 2,226.6 2,189.8 Corporate 158.7 173.1 Total $ 6,548.5 $ 6,274.5
Schedule of net sales to unaffiliated customers by country of domicile	Geographic information: Three Months Ended January 31, (In millions) 2020 2019 Net sales to unaffiliated customers by country of domicile: United States $ 293.5 $ 278.9 Europe 213.4 209.7 Rest of world 139.3 139.5 Total $ 646.2 $ 628.1
Schedule of net property, plant and equipment by country of domicile	(In millions) January 31, 2020 October 31, 2019 Net property, plant and equipment by country of domicile: United States $ 649.6 $ 626.5 Europe 361.9 358.8 Rest of world 157.0 146.8 Total $ 1,168.5 $ 1,132.1

General (Details)

General (Details) - USD ($) $ in Millions	Jan. 31, 2020	Nov. 01, 2018
New Accounting Pronouncements or Change in Accounting Principle [Line Items]
Operating lease right-of-use assets	$ 264
Operating lease liability	$ 272.7
Accounting Standards Update 2016-16
New Accounting Pronouncements or Change in Accounting Principle [Line Items]
Cumulative effect, decrease to retained earnings		$ 13.3
Accounting Standards Update 2016-16 | Retained Earnings
New Accounting Pronouncements or Change in Accounting Principle [Line Items]
Cumulative effect, decrease to retained earnings		$ 13.3

Leases - Narrative (Details)

Leases - Narrative (Details) $ in Millions	Jan. 31, 2020USD ($)
Leases [Abstract]
Commitments under finance lease arrangements	$ 2.2
Operating lease, weighted average remaining lease term	11 years 9 months 18 days
Operating lease, weighted average discount rate	3.00%

Leases - Leases on the Consolid

Leases - Leases on the Consolidated Condensed Balance Sheet (Details) $ in Millions	Jan. 31, 2020USD ($)
Operating Leases
Operating lease right-of-use assets	$ 264
Operating lease liabilities, current	31.5
Operating lease liabilities, non-current	241.2
Total operating lease liabilities	$ 272.7

Leases - Lease Expense on Conso

Leases - Lease Expense on Consolidated Statements of Income (Details) $ in Millions	3 Months Ended
	Jan. 31, 2020USD ($)
Leases [Abstract]
Operating lease expense	$ 9.9
Short-term lease expense	1.1
Variable lease expense	$ 0.4

Leases - Supplemental Cash Flow

Leases - Supplemental Cash Flow Information (Details) $ in Millions	3 Months Ended
	Jan. 31, 2020USD ($)
Leases [Abstract]
Operating cash flows from operating leases	$ 9.9

Leases - Minimum Rental Payment

Leases - Minimum Rental Payments required under Operating Leases (Details) $ in Millions	Jan. 31, 2020USD ($)
Leases [Abstract]
Remainder of 2020	$ 29
2021	36.1
2022	32.3
2023	29
2024	27.3
2025 and thereafter	175.7
Total lease payments	329.4
Less: interest	56.7
Present value of lease liabilities	$ 272.7

Leases - Future Minimum Lease P

Leases - Future Minimum Lease Payments for Operating Leases under ASC 840 (Details) $ in Millions	Oct. 31, 2019USD ($)
Leases [Abstract]
2020	$ 38.5
2021	34.9
2022	31.2
2023	28
2024	26.5
2025 and thereafter	173.6
Total future minimum lease payments	$ 332.7

Acquisitions - Total Purchase C

Acquisitions - Total Purchase Consideration for Business and Asset Acquisitions (Details) - USD ($)	Jan. 31, 2020	Oct. 31, 2019	Oct. 31, 2018
Schedule Of Business Acquisitions And Asset Acquisition, By Acquisition [Line Items]
Goodwill	$ 2,445,900,000	$ 2,428,900,000	$ 2,392,100,000
Technology
Schedule Of Business Acquisitions And Asset Acquisition, By Acquisition [Line Items]
Total identifiable intangible assets	0	12.3
Customer relationships
Schedule Of Business Acquisitions And Asset Acquisition, By Acquisition [Line Items]
Total identifiable intangible assets	3.4	7.5
Trademarks
Schedule Of Business Acquisitions And Asset Acquisition, By Acquisition [Line Items]
Total identifiable intangible assets	0	10.2
Other
Schedule Of Business Acquisitions And Asset Acquisition, By Acquisition [Line Items]
Total identifiable intangible assets	0	0.1
Acquisitions 2019
Schedule Of Business Acquisitions And Asset Acquisition, By Acquisition [Line Items]
Total identifiable intangible assets	3.4
Goodwill	4
Net tangible assets	1.8
Total purchase price	$ 9.2
Acquisitions 2018
Schedule Of Business Acquisitions And Asset Acquisition, By Acquisition [Line Items]
Total identifiable intangible assets		30.1
Goodwill		29.8
Net tangible assets		7.3
Total purchase price		$ 67.2

Acquisitions - Paragard (Detail

Acquisitions - Paragard (Details)	3 Months Ended
	Jan. 31, 2020
Schedule Of Asset Acquisition [Line Items]
Useful life	14 years

Inventories (Details)

Inventories (Details) - USD ($) $ in Millions	Jan. 31, 2020	Oct. 31, 2019
Inventory Disclosure [Abstract]
Raw materials	$ 133.3	$ 131.4
Work-in-process	12.5	13.3
Finished goods	380.7	362.2
Inventories, net	$ 526.5	$ 506.9

Intangible Assets - Schedule of

Intangible Assets - Schedule of Goodwill (Details) - USD ($) $ in Millions	3 Months Ended	12 Months Ended
	Jan. 31, 2020	Oct. 31, 2019
Goodwill [Roll Forward]
Beginning balance	$ 2,428.9	$ 2,392.1
Net additions	4	36.1
Translation	13	0.7
Ending balance	2,445.9	2,428.9
CooperVision
Goodwill [Roll Forward]
Beginning balance	1,765.4	1,742.9
Net additions	0	14.1
Translation	13.3	8.4
Ending balance	1,778.7	1,765.4
CooperSurgical
Goodwill [Roll Forward]
Beginning balance	663.5	649.2
Net additions	4	22
Translation	(0.3)	(7.7)
Ending balance	$ 667.2	$ 663.5

Intangible Assets - Narrative (

Intangible Assets - Narrative (Details)	3 Months Ended
	Jul. 31, 2019USD ($)
Goodwill [Line Items]
Goodwill, Impairment Loss	$ 0

Intangible Assets - Schedule _2

Intangible Assets - Schedule of Other Intangible Assets (Details) - USD ($) $ in Millions	3 Months Ended
	Jan. 31, 2020	Jan. 31, 2019	Oct. 31, 2019
Finite-Lived Intangible Assets [Line Items]
Gross Carrying Amount	$ 1,999.8		$ 1,995.8
Accumulated Amortization	634.3		599.4
Intangible assets with definite lives, net	$ 1,365.5		1,396.4
Weighted Average Amortization Period (in years)	14 years
Amortization of intangibles	$ 34.9	$ 36.6
Intangible assets with indefinite lives, net	8.9		8.9
Total other intangibles, net	1,374.4		1,405.3
Trademarks
Finite-Lived Intangible Assets [Line Items]
Gross Carrying Amount	148.5		148.5
Accumulated Amortization	$ 29.8		27.3
Weighted Average Amortization Period (in years)	14 years
Composite intangible asset
Finite-Lived Intangible Assets [Line Items]
Gross Carrying Amount	$ 1,061.9		1,061.9
Accumulated Amortization	$ 159.3		141.6
Weighted Average Amortization Period (in years)	15 years
Technology
Finite-Lived Intangible Assets [Line Items]
Gross Carrying Amount	$ 400.2		399.9
Accumulated Amortization	$ 229.1		221.2
Weighted Average Amortization Period (in years)	11 years
Customer relationships
Finite-Lived Intangible Assets [Line Items]
Gross Carrying Amount	$ 361.4		357.6
Accumulated Amortization	$ 200.1		194
Weighted Average Amortization Period (in years)	13 years
License and distribution rights and other
Finite-Lived Intangible Assets [Line Items]
Gross Carrying Amount	$ 27.8		27.9
Accumulated Amortization	$ 16		$ 15.3
Weighted Average Amortization Period (in years)	11 years

Intangible Assets - Remaining A

Intangible Assets - Remaining Amortization Expenses for Intangible Assets with Definite Lives (Details) - USD ($) $ in Millions	Jan. 31, 2020	Oct. 31, 2019
Goodwill and Intangible Assets Disclosure [Abstract]
Remainder of 2020	$ 101.5
2020	135
2021	133.1
2022	130.9
2023	126.6
Thereafter	738.4
Intangible assets with definite lives, net	$ 1,365.5	$ 1,396.4

Debt - Schedule of Debt (Detail

Debt - Schedule of Debt (Details) - USD ($) $ in Millions	Jan. 31, 2020	Oct. 31, 2019
Short-term Debt
Short-term debt	$ 543	$ 563.7
Long-term Debt
Less: unamortized debt issuance cost	(1.5)	(1.6)
Long-term debt	1,233.7	1,262.6
Total debt	1,776.7	1,826.3
Overdraft and other credit facilities
Short-term Debt
Short-term debt	43	63.7
Term loans
Short-term Debt
Short-term debt	500	500
Term loans
Long-term Debt
Long-term debt, gross	1,000	1,000
Other
Long-term Debt
Long-term debt, gross	0.2	0.2
Revolving Credit Facility | Line of Credit
Long-term Debt
Long-term debt, gross	$ 235	$ 264

Debt - Narrative (Details)

Debt - Narrative (Details) - USD ($)	Sep. 27, 2019	Nov. 01, 2017	Mar. 01, 2016	Jan. 31, 2020	Oct. 31, 2019	Nov. 01, 2018
Schedule of Long Term And Short Term Debt Instruments [Line Items]
Short-term debt				$ 543,000,000	$ 563,700,000
Term loans
Schedule of Long Term And Short Term Debt Instruments [Line Items]
Short-term debt				500,000,000	500,000,000
Term loans
Schedule of Long Term And Short Term Debt Instruments [Line Items]
Debt outstanding				1,000,000,000	1,000,000,000
Line of Credit | Revolving Credit Facility
Schedule of Long Term And Short Term Debt Instruments [Line Items]
Debt outstanding				235,000,000	$ 264,000,000
Term Loan Agreement 2019 | Term loans
Schedule of Long Term And Short Term Debt Instruments [Line Items]
Debt instrument, face amount	$ 500,000,000
Debt term	364 days
Short-term debt				$ 500,000,000
Weighted average interest rate				2.35%
Term Loan Agreement 2019 | Term loans | Base Rate
Schedule of Long Term And Short Term Debt Instruments [Line Items]
Debt instrument, basis spread on variable rate	0.00%
Term Loan Agreement 2019 | Term loans | London Interbank Offered Rate (LIBOR)
Schedule of Long Term And Short Term Debt Instruments [Line Items]
Debt instrument, basis spread on variable rate	0.60%
Term Loan Agreement 2018 | Term loans
Schedule of Long Term And Short Term Debt Instruments [Line Items]
Debt instrument, face amount						$ 400,000,000
Term Loan Agreement 2017 | Term loans
Schedule of Long Term And Short Term Debt Instruments [Line Items]
Debt instrument, face amount		$ 1,425,000,000
Debt term		5 years
Debt outstanding				$ 1,000,000,000
Interest rate				2.91%
Term Loan Agreement 2017 | Term loans | Base Rate | Minimum
Schedule of Long Term And Short Term Debt Instruments [Line Items]
Debt instrument, basis spread on variable rate		0.00%
Term Loan Agreement 2017 | Term loans | Base Rate | Maximum
Schedule of Long Term And Short Term Debt Instruments [Line Items]
Debt instrument, basis spread on variable rate		0.75%
Term Loan Agreement 2017 | Term loans | London Interbank Offered Rate (LIBOR) | Minimum
Schedule of Long Term And Short Term Debt Instruments [Line Items]
Debt instrument, basis spread on variable rate		1.00%
Term Loan Agreement 2017 | Term loans | London Interbank Offered Rate (LIBOR) | Maximum
Schedule of Long Term And Short Term Debt Instruments [Line Items]
Debt instrument, basis spread on variable rate		1.75%
Credit Agreement 2016 | Line of Credit | Revolving Credit Facility
Schedule of Long Term And Short Term Debt Instruments [Line Items]
Aggregate principal amount			$ 1,000,000,000
Debt outstanding				$ 235,000,000
Amount available under revolving credit facility				763,800,000
Credit Agreement 2016 | Line of Credit | Revolving Credit Facility | Minimum
Schedule of Long Term And Short Term Debt Instruments [Line Items]
Commitment fee percentage			0.125%
Credit Agreement 2016 | Line of Credit | Revolving Credit Facility | Maximum
Schedule of Long Term And Short Term Debt Instruments [Line Items]
Commitment fee percentage			0.25%
Credit Agreement 2016 | Line of Credit | Term Loan Facility 2016
Schedule of Long Term And Short Term Debt Instruments [Line Items]
Aggregate principal amount			$ 830,000,000
Potential additional borrowing capacity			$ 750,000,000
Debt outstanding				$ 0
Credit Agreement 2016 | Line of Credit | Revolving Credit Facility and Term Loan Facility 2016
Schedule of Long Term And Short Term Debt Instruments [Line Items]
Required minimum interest coverage ratio			3
Required maximum total leverage ratio			3.75
Credit Agreement 2016 | Line of Credit | Revolving Credit Facility and Term Loan Facility 2016 | Base Rate | Minimum
Schedule of Long Term And Short Term Debt Instruments [Line Items]
Debt instrument, basis spread on variable rate			0.00%
Credit Agreement 2016 | Line of Credit | Revolving Credit Facility and Term Loan Facility 2016 | Base Rate | Maximum
Schedule of Long Term And Short Term Debt Instruments [Line Items]
Debt instrument, basis spread on variable rate			0.75%
Credit Agreement 2016 | Line of Credit | Revolving Credit Facility and Term Loan Facility 2016 | London Interbank Offered Rate (LIBOR) | Minimum
Schedule of Long Term And Short Term Debt Instruments [Line Items]
Debt instrument, basis spread on variable rate			1.00%
Credit Agreement 2016 | Line of Credit | Revolving Credit Facility and Term Loan Facility 2016 | London Interbank Offered Rate (LIBOR) | Maximum
Schedule of Long Term And Short Term Debt Instruments [Line Items]
Debt instrument, basis spread on variable rate			1.75%
Term Loan Agreement 2018 and 2017 and Credit Agreement 2016
Schedule of Long Term And Short Term Debt Instruments [Line Items]
Interest coverage ratio				15.26
Total leverage ratio				1.82

Income Taxes - Narrative (Detai

Income Taxes - Narrative (Details) - USD ($) $ in Millions	3 Months Ended
	Jan. 31, 2020	Jan. 31, 2019	Oct. 31, 2019
Income Tax Disclosure [Abstract]
Effective income tax rate expense (benefit)	7.10%	(10.00%)
Discrete tax benefits	$ 3.8
Unrecognized tax benefits	54.8		$ 49.7
Unrecognized tax benefits that could be settled during the next twelve months	$ 14.8

Earnings Per Share - Schedule o

Earnings Per Share - Schedule of Earnings Per Share (Details) - USD ($) $ / shares in Units, shares in Millions, $ in Millions	3 Months Ended
	Jan. 31, 2020	Jan. 31, 2019
Earnings Per Share [Abstract]
Net income	$ 90.5	$ 103.2
Basic:
Weighted average common shares (in shares)	49.1	49.3
Basic earnings per share (in dollars per share)	$ 1.84	$ 2.09
Diluted:
Effect of potential dilutive shares (in shares)	0.6	0.6
Diluted weighted average common shares (in shares)	49.7	49.9
Diluted earnings per share attributable to Cooper stockholders (in dollars per share)	$ 1.82	$ 2.07

Earnings Per Share - Schedule_2

Earnings Per Share - Schedule of Stock Options and Restricted Stock Units that were not Included in the Diluted Earnings Per Share Calculation (Details) - $ / shares shares in Thousands	3 Months Ended
	Jan. 31, 2020	Jan. 31, 2019
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Range of exercise prices, lower limit	$ 254.77	$ 226.3
Range of exercise prices, upper limit	$ 254.77	$ 254.77
Stock Options
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Number of stock option shares and restricted stock units excluded (in shares)	198	377
Restricted Stock Units (RSUs)
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Number of stock option shares and restricted stock units excluded (in shares)	1	17

Share-Based Compensation Plan_2

Share-Based Compensation Plans - Schedule of Compensation Expense and Related Income Tax Benefit for Share-Based Awards (Details) - USD ($) $ in Millions	3 Months Ended
	Jan. 31, 2020	Jan. 31, 2019
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Total share-based compensation expense	$ 10.3	$ 11.7
Related income tax benefit	1.4	1.7
Selling, general and administrative expense
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Total share-based compensation expense	8.7	9.3
Cost of sales
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Total share-based compensation expense	1	1.5
Research and development expense
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Total share-based compensation expense	$ 0.6	$ 0.9

Share-Based Compensation Plan_3

Share-Based Compensation Plans - Narrative (Details) - shares shares in Millions	Jan. 31, 2020	Oct. 31, 2019
Share-based Payment Arrangement [Abstract]
Treasury stock (in shares)	4.1	4.1

Stockholders' Equity - Schedule

Stockholders' Equity - Schedule of Changes in Accumulated Other Comprehensive Income (Loss) Income (Details) - USD ($) $ in Millions	3 Months Ended	12 Months Ended
	Jan. 31, 2020	Oct. 31, 2018
AOCI Attributable to Parent, Net of Tax [Roll Forward]
Beginning balance	$ 3,628.6
Gross change in value		$ (24.4)
Tax effect for the period		8
Gross change in value	16.7
Ending balance	3,730.9	3,307.8
Foreign Currency Translation Adjustment
AOCI Attributable to Parent, Net of Tax [Roll Forward]
Beginning balance	(403.2)
Gross change in value		9
Tax effect for the period		0
Gross change in value	16.7
Ending balance	(386.5)	(412.2)
Minimum Pension Liability
AOCI Attributable to Parent, Net of Tax [Roll Forward]
Beginning balance	(43.9)
Gross change in value		(33.4)
Tax effect for the period		8
Gross change in value	0
Ending balance	(43.9)	(18.5)
Accumulated Other Comprehensive Income (Loss)
AOCI Attributable to Parent, Net of Tax [Roll Forward]
Beginning balance	(447.1)
Ending balance	$ (430.4)	$ (430.7)

Stockholders' Equity - Share Re

Stockholders' Equity - Share Repurchases (Details) - USD ($)	3 Months Ended		12 Months Ended
	Jan. 31, 2020	Jan. 31, 2019	Oct. 31, 2019	Mar. 31, 2017	Dec. 31, 2011
Stockholders' Equity Note [Abstract]
Share repurchase program, authorized amount for repurchase				$ 1,000,000,000	$ 500,000,000
Share repurchase program, common stock repurchased (in shares)	0		537,000
Share repurchase program, common stock repurchased		$ 6,100,000	$ 156,100,000
Share repurchase program, remaining authorized amount for repurchase	$ 407,400,000

Stockholders' Equity - Dividend

Stockholders' Equity - Dividends (Details) - Subsequent Event $ / shares in Units, $ in Millions	Feb. 10, 2020USD ($)$ / shares
Subsequent Event [Line Items]
Dividends on common stock | $	$ 1.5
Dividends on common stock (in dollars per share) | $ / shares	$ 0.03

Fair Value Measurements (Detail

Fair Value Measurements (Details) - USD ($)	Jan. 31, 2020	Oct. 31, 2019
Fair Value Disclosures [Abstract]
Derivative asset	$ 0	$ 0
Derivative liability	$ 0	$ 0

Employee Benefits - Schedule of

Employee Benefits - Schedule of Components of Net Periodic Defined Benefit Costs (Details) - USD ($) $ in Millions	3 Months Ended
	Jan. 31, 2020	Jan. 31, 2019
Retirement Benefits [Abstract]
Service cost	$ 3.5	$ 2.5
Interest cost	1.2	1.5
Expected return on plan assets	(2.7)	(2.4)
Recognized net actuarial loss	1	0.2
Net periodic defined benefit plan cost	$ 3	$ 1.8

Employee Benefits - Narrative (

Employee Benefits - Narrative (Details) - USD ($)	3 Months Ended
	Jan. 31, 2020	Jan. 31, 2019
Retirement Benefits [Abstract]
Defined benefit plan, contributions by employer	$ 0	$ 0
Defined benefit plan, expected contributions by employer for remainder of fiscal year	$ 10,000,000
Expected rate of return on plan assets for determining net periodic pension cost	8.00%

Contingencies (Details)

Contingencies (Details) $ in Millions	1 Months Ended	4 Months Ended
	Jul. 31, 2018USD ($)	Jun. 30, 2015action
Commitments and Contingencies Disclosure [Abstract]
Number of putative class action complaints filed (over) | action		50
Coopervision Litigation
Loss Contingencies [Line Items]
Litigation settlement amount | $	$ 3

Business Segment Information -

Business Segment Information - Narrative (Details)	3 Months Ended
	Jan. 31, 2020segment
Segment Reporting [Abstract]
Number of operating segments	2

Business Segment Information _2

Business Segment Information - Schedule of Segment Information (Details) - USD ($) $ in Millions	3 Months Ended
	Jan. 31, 2020	Jan. 31, 2019
Segment Reporting Information [Line Items]
Total net sales	$ 646.2	$ 628.1
Total operating income	111.1	110.9
Interest expense	11.6	18.2
Other expense (income), net	2.1	(1.1)
Income before income taxes	97.4	93.8
CooperVision
Segment Reporting Information [Line Items]
Total net sales	485.2	470.1
CooperSurgical
Segment Reporting Information [Line Items]
Total net sales	161	158
Toric lens | CooperVision
Segment Reporting Information [Line Items]
Total net sales	155.1	146
Multifocal lens | CooperVision
Segment Reporting Information [Line Items]
Total net sales	51.8	49.1
Single-use sphere lens | CooperVision
Segment Reporting Information [Line Items]
Total net sales	138.1	132.1
Non single-use sphere, other | CooperVision
Segment Reporting Information [Line Items]
Total net sales	140.2	142.9
Office and surgical products | CooperSurgical
Segment Reporting Information [Line Items]
Total net sales	98.5	95.7
Fertility | CooperSurgical
Segment Reporting Information [Line Items]
Total net sales	62.5	62.3
Operating Segments | CooperVision
Segment Reporting Information [Line Items]
Total operating income	122.9	116.3
Operating Segments | CooperSurgical
Segment Reporting Information [Line Items]
Total operating income	1.7	7.2
Corporate
Segment Reporting Information [Line Items]
Total operating income	$ (13.5)	$ (12.6)

Business Segment Information _3

Business Segment Information - Schedule of Identifiable Assets by Segment (Details) - USD ($) $ in Millions	Jan. 31, 2020	Oct. 31, 2019
Segment Reporting Information [Line Items]
Total Identifiable assets	$ 6,548.5	$ 6,274.5
Operating Segments | CooperVision
Segment Reporting Information [Line Items]
Total Identifiable assets	4,163.2	3,911.6
Operating Segments | CooperSurgical
Segment Reporting Information [Line Items]
Total Identifiable assets	2,226.6	2,189.8
Corporate
Segment Reporting Information [Line Items]
Total Identifiable assets	$ 158.7	$ 173.1

Business Segment Information _4

Business Segment Information - Schedule of Net Sales to Unaffiliated Customers by Country of Domicile (Details) - USD ($) $ in Millions	3 Months Ended
	Jan. 31, 2020	Jan. 31, 2019
Revenues from External Customers and Long-Lived Assets [Line Items]
Total net sales	$ 646.2	$ 628.1
United States
Revenues from External Customers and Long-Lived Assets [Line Items]
Total net sales	293.5	278.9
Europe
Revenues from External Customers and Long-Lived Assets [Line Items]
Total net sales	213.4	209.7
Rest of world
Revenues from External Customers and Long-Lived Assets [Line Items]
Total net sales	$ 139.3	$ 139.5

Business Segment Information _5

Business Segment Information - Schedule of Net Property, Plant and Equipment By Country of Domicile (Details) - USD ($) $ in Millions	Jan. 31, 2020	Oct. 31, 2019
Revenues from External Customers and Long-Lived Assets [Line Items]
Net property, plant and equipment	$ 1,168.5	$ 1,132.1
United States
Revenues from External Customers and Long-Lived Assets [Line Items]
Net property, plant and equipment	649.6	626.5
Europe
Revenues from External Customers and Long-Lived Assets [Line Items]
Net property, plant and equipment	361.9	358.8
Rest of world
Revenues from External Customers and Long-Lived Assets [Line Items]
Net property, plant and equipment	$ 157	$ 146.8

Uncategorized Items - coo202001

Label	Element	Value
Restricted Cash and Cash Equivalents, Current	us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue	$ 600,000
Restricted Cash and Cash Equivalents, Current	us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue	$ 300,000